BioSpace News Archive

Apollo Medical Holdings, Inc., a leading physician-centric, technology-powered healthcare management company, announced it has appointed Chief Technology Officer Brandon Sim to the role of Chief Operating Officer, effective February 3, 2021.

MedAvail, Inc., a technology-enabled retail pharmacy company driving best in class medication adherence by embedding its pharmacy services directly into Medicare-focused clinics using its proprietary MedCenter solution, announced that it is partnering with Cigna Medical Group to provide patients an additional safe and convenient way to receive medications through MedAvail’s SpotRx pharmacy kiosks.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, announced that executive leadership will be participating in the following upcoming investor conferences:

Bristol Myers Squibb, the biopharmaceutical company that discovers, develops and delivers innovative medicines to help patients prevail over serious diseases, and Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, announce ten finalists chosen for the Lyfebulb-Bristol Myer Squibb “Addressing Unmet Needs in MS: An Innovation Challenge”.

Synaptogenix, Inc. (OTC: SNPX) (the “Company”), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that it has submitted a formal application to list its common shares on the Nasdaq Stock Market (“Nasdaq”).

Dorian Therapeutics, a biotechnology company that develops treatments for age-related diseases leveraging its proprietary senoblocker technology, today announced that Jeff George has been appointed to the company’s Board of Directors

Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema.

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round of $17.4 million.

908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced the appointment of industry veteran Steve Davenport as Vice President of Commercial Sales.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that 11 new partner programs entered clinical development in 2020.